Literature DB >> 3547270

Seroimmunology of AIDS retrovirus infection. I. Use of immunofluorescence assay to confirm sera with ELISA reactivity.

A A Imrie, S Kehrer, G W Smith, R Penny, D A Cooper.   

Abstract

One thousand sera shown to be reactive by one of two commercial enzyme linked immunosorbent assays (ELISA) for antibodies to the AIDS virus were referred to the NSW State Reference Laboratory for confirmatory assays. Each serum was retested by two commercial ELISA systems (Abbott and ENI), the ENI exclusionary H9 ELISA and an immunofluorescence assay. Three hundred and twenty four sera were reactive by all 3 tests whereas 244 demonstrated concordant non-reactivity. Three hundred and seventy seven sera were reactive by Abbott EIA only and could not be confirmed positive by the ENI ELISA incorporating exclusionary testing, immunofluorescence or Western immunoblot of representative sera. Sera obtained from teaching hospital laboratories were more likely to be positive and less likely to be negative by all 3 tests, and were also less likely to be Abbott EIA reactive only compared with sera obtained from the blood transfusion service. Of the remaining 55 sera, 52 demonstrated a negative immunofluorescent reaction or a pattern of equal fluorescence on AIDS virus infected and control cells. Representative sera were shown to be negative on Western immunoblot analysis. Of the 3 sera which demonstrated immunofluorescence reactivity, one was positive and one was negative by Western immunoblot, and one could not be determined. We conclude that a combination of two ELISAs, one with an exclusionary ELISA test and an immunofluorescence assay is a reliable and simple means of confirming reactive sera for AIDS virus antibodies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3547270     DOI: 10.3109/00313028609087565

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  6 in total

Review 1.  Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution.

Authors:  Thomas S Alexander
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Immunofluorescence assay for human immunodeficiency virus antibody: investigation of cell fixation for virus inactivation and antigen preservation.

Authors:  M Fauvel; G Ozanne
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

3.  Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.

Authors:  B Forghani; J W Hurst; C S Chan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

4.  Human immunodeficiency virus and female prostitutes, Sydney 1985.

Authors:  C R Philpot; C Harcourt; J Edwards; A Grealis
Journal:  Genitourin Med       Date:  1988-06

5.  Immunofluorescence assay for detection of antibodies to human immunodeficiency virus type 2.

Authors:  B B Kvinesdal; C M Nielsen; A G Poulsen; N Højlyng
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

Review 6.  Acquired immunodeficiency syndrome: more than a health-related dilemma.

Authors:  M J Severin
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.